The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as ...
06:21 EDT 9 Sep 2012 | LaMerie
Phase 3 Trial to be Conducted Across Sites in Asia and Europe
Original Article: The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as ...
More From BioPortfolio on "The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
